There are not many issues you can hear both Republicans and Democrats clapping about in unison, but high drug prices is definitely one of them. Echoing his 2016 campaign, President Trump again proclaimed during his State of the Union address Tuesday night that his administration is determined “to make fixing the injustice of high drug prices one of our top priorities.”
Speeding up the approval of lower-cost generics was noted by Trump as “exciting progress,” but nothing substantial has been done by the Trump administration on drug prices. The appointment of Alex Azar to head the Department of Health and Human Services department was a major disappointment. As president of Eli Lilly USA, Azar oversaw major price hikes on lifeline medications, such as insulin.
Appealing to both his base and popular opinion, President Trump could use his executive authority immediately to more expressly permit Americans to buy medication from international pharmacies.
Tagged with: Alex Azar, Eli Lilly, executive authority, State of The Union, trump
Last month, I published an op-ed in The Guardian in opposition to Alex Azar for Secretary of Health and Human Services. In advance of the Senate Finance Committee Hearing tomorrow over his nomination, I’m publishing my article in its entirety below.
Recently, the president announced Alex Azar as his nominee to lead the US Department of Health and Human Services, saying: “He will be a star for better healthcare and lower drug prices!” People like me – experts in drug policy and advocates for lowering drug costs for American patients – know that nothing could be farther from the truth.
On average, Americans pay twice as much for life-saving drugs as consumers in other developed countries. It doesn’t have to be this way, but unfortunately, Azar might think so.
On Wednesday, Azar appeared before the Senate Health, Education, Labor and Pensions committee. While he stated his commitment to lowering drug prices, he declined to support the two solutions that would have the greatest impact on patients. In fact, he and his company have vigorously opposed policies that would make healthcare more affordable for the rest of us. (more…)
Tagged with: Alex Azar, Eli Lilly, HHS
Alex Azar and Eli Lilly have opposed policies that would make healthcare more affordable for Americans. Photo: Michael Reynolds/EPA
As I wrote a few weeks back on these blog pages, President Trump’s nomination of Alex Azar to lead the Department of Health and Human Services will help Big Pharma continue to get away with murder; something the president says he opposes. Mr. Azar just left Eli Lilly USA earlier this year as its president. Under his tenure with Lilly, Azar vehemently opposed importing lower-cost medications from Canada among other polices to tackle high drug prices.
In my capacity as founder of Prescription Justice, I published an op-ed in The Guardian called “Alex Azar is big pharma personified. He must not become US health secretary.” A Big Pharma executive is not the right pick to get this country moving on lowering drug prices. I’m just saying…
Tagged with: Alex Azar, Big Pharma, Drug Importation, Eli Lilly, HHS